NATIONAL SCIENCE ADVISORY BOARD FOR BIOSECURITY

National Institutes of Health
Bldg. 31, C Wing, 6th Floor, Conference Room 6
9000 Rockville Pike
Bethesda, MD

September 28, 2015

MEETING AGENDA

8:30 – 8:50 am	**Welcome and Introductions**
8:30 – 8:35 am	**Opening Remarks** ***Samuel L. Stanley, M.D.*** *NSABB Chair* *President, Stony Brook University*
8:35 – 8:45 am	**Introduction of NSABB Voting and *Ex Officio* Members** ***Christopher J. Viggiani, Ph.D.*** *Executive Director, NSABB* *National Institutes of Health* **Review of Conflict of Interest Rules** ***Christopher J. Viggiani, Ph.D.***
8:45 – 8:50 am	**Approval of NSABB Meeting Minutes** ***Samuel L. Stanley, M.D.***
8:50 – 9:50 am	**Update from the NSABB Working Group**
8:50 – 9:20 am	**Update from the Working Group on Evaluating Risks and Benefits of GOF Studies Involving Pathogens with Pandemic Potential** ***Joseph Kanabrocki, Ph.D., C.B.S.P.*** *Co-chair, NSABB Working Group* *Associate Vice President for Research Safety* *Professor of Microbiology* *University of Chicago*
9:20 – 9:50 am	**NSABB Discussion**
9:50 – 10:00 am	**Break**
10:00 – 11:30 am	**Update and Discussion of Risk-Benefit Assessment for Gain-of-Function Studies**
10:00 – 10:45 am	**Progress Report and Laboratory Risk Assessment** ***Rocco Casagrande, Ph.D.*** *Principal Investigator* *Managing Director, Gryphon Scientific*

Biosecurity Risk Assessment
Kavita Berger, Ph.D.
Scientist, Gryphon Scientific

Benefit Assessment
Corey Meyer, Ph.D.
Senior Analyst, Gryphon Scientific

10:45 – 11:30 am **NSABB Discussion**

11:30 – 11:50 am **Public Comments (Session I)**

11:50 – 12:15 pm **Break to Get Lunches for Working Lunch**

12:15 – 1:30 pm **The Ethical, Legal, and Policy Issues Associated with Gain-of-Function Studies (WORKING LUNCH)**

Format: *Presentation by author of commissioned ethics analysis followed by comments/remarks by 2 panelists; moderated discussion among panelists and NSABB discussion*

Questions to be considered during the presentations and discussions:

- *What values and decision-making frameworks should NSABB consider in moving beyond the risk/benefit assessment in order to formulate policy recommendations on GOF studies involving pathogens with pandemic potential?*
- *Is there GOF research that should not be funded and conducted? If so, what are the features of such studies and what considerations should guide the identification of GOF studies that might meet such designation?*
- *After considering risks and benefits, what policy options or oversight strategies might NSABB consider in generating recommendations to the U.S. Government on the funding and conduct of GOF studies involving pathogens with pandemic potential?*

Moderator: Susan Wolf, J.D.
Member, NSABB
McKnight Presidential Professor of Law, Medicine & Public Policy
Faegre Baker Daniels Professor of Law
Professor of Medicine
University of Minnesota Law School

Presenter: Michael Selgelid, Ph.D.
Director, Center for Human Bioethics
Professor of Bioethics
School of Philosophical, Historical and International Studies
Monash University

Panelists:

Rebecca Dresser, J.D.
Daniel Noyes Kirby Professor of Law
Professor of Ethics in Medicine
Washington University in St. Louis

Eric Meslin, Ph.D.
Director, Indiana University Center for Bioethics
Associate Dean and Professor of Bioethics,
Indiana University School of Medicine
Managing Director, Center for Law, Ethics and Applied Research in Health Information

1:00 – 1:30 pm	**NSABB Discussion**
1:30 – 1:50 pm	**Public Comments (Session II)**
1:50 – 2:05 pm	**Break**
2:05 – 3:50 pm	**NSABB Discussion**
	Samuel L. Stanley, M.D.
3:50 – 4:00 pm	**Concluding Remarks and Adjourn**
	Samuel L. Stanley, M.D.